[Gabitril as an additive drug in therapy of intractable epileptic seizures in children].
Tiagabine (Gabitril, Sanofi Synlhelabo) new antiepileptic drug was used in add-on therapy in 25 children with resistant partial complex and secondary generalized seizures. Treatment was carried out in children aged 4-17 years with low dose escalation from 5 to 45 mg/day, in three doses until good clinical effects were obtained. In 3 patients aged 4 years, in 11 children aged 5-12 years and in 11 children aged above 17 years Gabitril was used. Follow up period was 8-10 months. Frequency of epileptic seizures before implementation of Gabitril treatment, even during polytherapy with 2 or more antiepileptic drugs was several to hundred per day (status epilepticus was observed in 2 children with Rasmussen syndrome). During the observation 5 children became seizure free, in 11 patients reduction in seizures frequency above 50% was observed and in 9 children effects of treatment were not good enough. Gabitril was well tolerated, and any adverse events were observed in add-on therapy. Preliminary observation and good results of add-on therapy with Gabitril are positive. Drug is safe and generally well-tolerated with good effects at add-on therapy in 64% children with resistant partial complex and secondary generalized seizures.
Klinika Neurologii Dzieciecej Instytutu Pomnik Centrum Zdrowia Dziecka w Warszawie.
T
T
Kmieć
S
S
Jóźwiak
D
D
Kuczyński
B
B
Karkowska
M
M
Bachański
D000293:Adolescent; D000927:Anticonvulsants / Q000008:administration & dosage*; D002220:Carbamazepine / Q000008:administration & dosage / Q000031:analogs & derivatives; D002648:Child; D002675:Child, Preschool; D002998:Clonazepam / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D004829:Epilepsy, Generalized / Q000188:drug therapy*; D000078328:Felbamate; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D009557:Nipecotic Acids / Q000008:administration & dosage*; D009567:Nitrazepam / Q000008:administration & dosage; D000078330:Oxcarbazepine; D048448:Phenylcarbamates; D010672:Phenytoin / Q000008:administration & dosage; D011409:Propylene Glycols / Q000008:administration & dosage; D000078308:Tiagabine; D014227:Triazines / Q000008:administration & dosage; D014635:Valproic Acid / Q000008:administration & dosage; D020888:Vigabatrin / Q000008:administration & dosage
D000927:Anticonvulsants; D009557:Nipecotic Acids; D048448:Phenylcarbamates; D011409:Propylene Glycols; D014227:Triazines; D002220:Carbamazepine; D002998:Clonazepam; D014635:Valproic Acid; D010672:Phenytoin; D009567:Nitrazepam; D020888:Vigabatrin; D000077213:Lamotrigine; D000078330:Oxcarbazepine; D000078328:Felbamate; D000078308:Tiagabine